Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series

J B Jeans1, K Savik, C R Gross

  • 1Watson Laboratory, University of Minnesota, Minneapolis, USA.

Insights

Patients with acute intermittent porphyria (AIP) face a three-fold higher mortality risk. Porphyric attacks, not suicide, were the primary cause of death in this genetic disorder over a 50-year period.

Area of Science:

  • Medical Genetics
  • Clinical Neurology
  • Epidemiology

Background:

  • Acute intermittent porphyria (AIP) is a rare genetic disorder characterized by severe neurologic dysfunction during attacks.
  • Hospitalization for porphyric attacks indicates a severe manifestation of AIP with potential for life-threatening complications.

Purpose of the Study:

  • To determine the long-term prognosis and mortality rates for patients hospitalized with AIP in the United States.
  • To analyze causes of death and compare survival before and after the introduction of hematin therapy.

Main Methods:

  • Retrospective cohort study of 136 AIP patients hospitalized between 1940 and 1988.
  • Diagnosis confirmed by clinical symptoms and elevated urinary porphobilinogen.
  • Survival analysis compared to age-matched US population using 1970 Census Death Rates.

Main Results:

  • A standardized mortality ratio of 3.2 (95% CI: 2.4-4.0) was observed, indicating a three-fold increased mortality risk compared to the general population.
  • The majority of deaths (58%) occurred during or subsequent to a porphyric attack.
  • Suicide accounted for five deaths.
  • While survival appeared improved after 1971 (introduction of hematin therapy), the difference was not statistically significant.

Conclusions:

  • Symptomatic AIP significantly increases mortality risk, approximately threefold, over a 50-year period.
  • Porphyric attacks themselves are the predominant cause of excess mortality in AIP patients.
  • Further research may be needed to confirm the long-term survival benefits of newer therapies like hematin.